Catalyst Pharmaceuticals, Inc. continued to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues as compared to 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.87 USD | -4.21% | -1.65% | -5.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.57% | 187.57Cr | |
-2.91% | 8.9TCr | |
-4.34% | 3.78TCr | |
-17.08% | 3.12TCr | |
+59.89% | 2.61TCr | |
-22.15% | 1.43TCr | |
-9.36% | 1.28TCr | |
-11.39% | 1.16TCr | |
-46.06% | 1.09TCr | |
+3.00% | 870.27Cr |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022